News & Updates

Long-term follow-up of the DESTINY-Breast03 trial has reported a median overall survival (OS) of 52.6 months with trastuzumab deruxtecan (T-DXd), representing the longest reported OS in previously treated HER2-positive metastatic breast cancer (mBC) to date. 

Patients suffering from gastroesophageal reflux disease (GERD) and ineffective esophageal motility (IEM) may benefit from the novel RefluxStop device implantation, a safe and minimally invasive technology that offers potential benefits, a study has shown.

Oral supplementation with cyanocobalamin 1,000 μg/d helps treat vitamin B12 deficiency associated with pernicious anaemia (PA), reports a study.

A French study presented at EULAR 2024 reveals an association between statin treatment and an increased risk of total joint replacement in individuals with knee and hip osteoarthritis (OA).

Semaglutide reduces the risk of major kidney disease-related events and death from cardiovascular causes in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD), as shown in the FLOW* study presented at ERA 2024. 

Fludarabine, melphalan, and total marrow irradiation (TMI) 900 cGy may be utilized as conditioning for allogeneic stem cell transplantation in patients with high-risk or relapsed/refractory multiple myeloma, as shown in a phase I trial.